We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
BioCryst Pharmaceuticals announced that Fodosine has been granted orphan status for the treatment of cutaneous T-cell lymphoma (CTCL) by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA).
ViroPharma announced that the FDA has granted orphan drug designation for maribavir for prevention of cytomegalovirus (CMV) viremia and disease in at-risk populations.
Gloucester Pharmaceuticals announced that the first patient has been treated in a Phase I/II investigator-initiated clinical study of romidepsin in combination with bortezomib to treat patients with relapsed/refractory multiple myeloma.
CytRx has announced its plans for completing the next step towards initiating its Phase IIb clinical trial for the treatment of amyotrophic lateral sclerosis (ALS), planned to begin in the third quarter of this year.
Threshold Pharmaceuticals has initiated patient enrollment in a Phase II clinical trial evaluating the efficacy and safety of glufosfamide in patients with recurrent, sensitive, small-cell lung cancer.
Biogen Idec has initiated a randomized, controlled registration trial of an investigational anti-CD23 monoclonal antibody, lumiliximab, for patients with chronic lymphocytic leukemia (CLL).
Ilypsa has completed enrollment in its Phase II clinical trial of ILY101 in the U.S. ILY101 is a novel phosphate-binding agent for the treatment of hyperphosphatemia, a serious complication in patients with kidney disease on dialysis.
Genta has announced it will appeal the not approvable letter from the FDA for its new drug application (NDA) for the use of Genasense (oblimersen sodium) injection plus chemotherapy in patients with chronic lymphocytic leukemia (CLL).